These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35316701)

  • 1. Paying for pharmaceuticals: uniform pricing versus two-part tariffs.
    Brekke KR; Dalen DM; Straume OR
    J Health Econ; 2022 May; 83():102613. PubMed ID: 35316701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The price of cost-effectiveness thresholds under therapeutic competition in pharmaceutical markets.
    Brekke KR; Dalen DM; Straume OR
    J Health Econ; 2023 Jul; 90():102778. PubMed ID: 37343309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The economics of alternative payment models for pharmaceuticals.
    Hlávka JP; Yu JC; Goldman DP; Lakdawalla DN
    Eur J Health Econ; 2021 Jun; 22(4):559-569. PubMed ID: 33725260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme.
    Karnon J; Edney L; Sorich M
    Aust Health Rev; 2017 Mar; 41(1):1-6. PubMed ID: 26954612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential pricing for pharmaceuticals: reconciling access, R&D and patents.
    Danzon PM; Towse A
    Int J Health Care Finance Econ; 2003 Sep; 3(3):183-205. PubMed ID: 14625999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reference pricing with endogenous generic entry.
    Brekke KR; Canta C; Straume OR
    J Health Econ; 2016 Dec; 50():312-329. PubMed ID: 27350294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden.
    Davidova J; Praznovcova L; Lundborg CS
    Pharm World Sci; 2008 Jan; 30(1):57-64. PubMed ID: 17588212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
    Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An assessment of innovative pricing schemes for the communication of value: is price discrimination and two-part pricing a way forward?
    Hertzman P; Miller P; Tolley K
    Expert Rev Pharmacoecon Outcomes Res; 2018 Feb; 18(1):5-12. PubMed ID: 29186996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endogenous versus exogenous generic reference pricing for pharmaceuticals.
    Antoñanzas F; Juárez-Castelló CA; Rodríguez-Ibeas R
    Int J Health Econ Manag; 2017 Dec; 17(4):413-432. PubMed ID: 28508248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Five-year examination of utilization and drug cost outcomes associated with benefit design changes including reference pricing for proton pump inhibitors in a state employee health plan.
    Johnson JT; Neill KK; Davis DA
    J Manag Care Pharm; 2011 Apr; 17(3):200-12. PubMed ID: 21434697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The reference pricing of pharmaceuticals in European countries].
    Gildeyeva GN; Starykh DA
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2013; (3):45-9. PubMed ID: 24027849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmaceutical pricing; what is reasonable?].
    Versteegh MM
    Ned Tijdschr Geneeskd; 2020 Aug; 164():. PubMed ID: 32940991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug price regulation under consumer moral hazard. Two-part tariffs, uniform price or third-degree price discrimination?
    Felder S
    Eur J Health Econ; 2004 Dec; 5(4):324-9. PubMed ID: 15759171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The European enigma of pharmaceutical pricing: still solvable?].
    Badinella Martini M; Finazzi B; Garattini L
    Recenti Prog Med; 2022 Jun; 113(6):355-358. PubMed ID: 35758112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pricing strategies, executive committee power and negotiation leverage in New Zealand's containment of public spending on pharmaceuticals.
    Main B; Csanadi M; Ozieranski P
    Health Econ Policy Law; 2022 Jul; 17(3):348-365. PubMed ID: 35382921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of mail-order with community pharmacy in plan sponsor cost and member cost in two large pharmacy benefit plans.
    Johnsrud M; Lawson KA; Shepherd MD
    J Manag Care Pharm; 2007 Mar; 13(2):122-34. PubMed ID: 17330973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential pricing of new pharmaceuticals in lower income European countries.
    Kaló Z; Annemans L; Garrison LP
    Expert Rev Pharmacoecon Outcomes Res; 2013 Dec; 13(6):735-41. PubMed ID: 24219049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abandoning List Prices In Medicaid Drug Reimbursement Did Not Affect Spending.
    Ippolito B; Levy JF; Anderson GF
    Health Aff (Millwood); 2020 Jul; 39(7):1202-1209. PubMed ID: 32634350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Importance of aligning the implementation of new payment models for innovative pharmaceuticals in European countries.
    Kaló Z; Niewada M; Bereczky T; Goettsch W; Vreman RA; Xoxi E; Trusheim M; Callenbach MHE; Nagy L; Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2024 Feb; 24(2):181-187. PubMed ID: 37970637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.